Shots:

• The NMPA has approved Lee pharma to initiate P-III clinical trials to evaluate Socazolimab + CT as a 1L treatment of ES-SCLC. The study is expected to initiate patient recruitment in Q2’21
• The clearance is based on the results from P- Ib trial in which Socazolimab + carboplatin and etoposide demonstrated a promising efficacy & safety profile in patients with ES- SCLC
• Socazolimab is a fully human anti-PD-L1 mAb- licensed from Sorrento to COF for the greater China territory. Earlier- Socazolimab has received NMPA’s BTD in Feb’2021 for recurrent or metastatic cervical cancer while Lee intends to file the NDA for the same indication in Q2’21

 ­ Ref: Sorrento | Image: PRNewswire